Advertisement

Advertisement
Lung Cancer

Studies Find Trilaciclib May Improve Chemotherapy Experience for Patients With Small Cell Lung Cancer

In patients with extensive-stage small cell lung cancer (SCLC), adding trilaciclib to standard-of-care chemotherapy demonstrated meaningful delays in deterioration of myelosuppression-related symptoms, according to Jared Weiss, MD, of the UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, and colleagues. Based on these findings, the investigators maintain that trilaciclib may make myelosuppressive chemotherapy safer.

 

Genomics/Genetics
Breast Cancer

How Laura J. van ’t Veer, PhD, Became an Expert in Genetic Testing for Breast Cancer

Breast cancer researcher and innovator Laura J. van ’t Veer, PhD, was born and reared in Amsterdam in 1957. “During high school, I had a wonderful biology teacher who was going through his own biology studies at the University of Amsterdam, and he was bringing that university-level education into my class, although I was only 14 years old at the time. I remember learning about genes—how they were the beginning of life and the drivers of how our body functions. I always loved science, but it was that rich experience that made me sure I wanted to pursue a career in medical research,” said Dr. van ’t Veer.

 

Leukemia
Geriatric Oncology
Health-Care Policy
Immunotherapy

Ibrutinib and Rituximab vs Standard Chemoimmunotherapy in CLL

In this week's podcast, we review a report on the combination of ibrutinib and rituximab vs standard chemoimmunotherapy in some patients...


Advertisement
Issues in Oncology

Gender Equity

Diversity, inclusion, and gender equality were prevalent themes for 2019 that ran throughout the ASCO Annual Meeting. From the first year that featured free onsite child care for attendees, to a session on “Establishing a Mutually Respectful Environment in the Workplace,” as well as a Plenary Session that highlighted health policy as a strategy to decrease disparities in care, it is exciting to see our field leading these important discussions. This approach is a necessity if we are going to create systemic change on a national scale.

Hematologic Malignancies

Highlights in Geriatric Hematology From the ASH Annual Meeting & Exposition

Many exciting studies were presented at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition and were covered in previous issues of The ASCO Post. In addition to a scientific workshop dedicated to hematology and aging, many abstracts focused specifically on older adults, and a few of these studies are featured here.

Advertisement




More Top Stories

Bladder Cancer
Immunotherapy

Matt D. Galsky, MD, on Urothelial Cancer: Pembrolizumab vs Placebo After First-Line Chemotherapy

Hematologic Malignancies
Lymphoma

Polatuzumab Vedotin-piiq for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

On June 10, 2019, the CD79b-directed antibody-drug conjugate polatuzumab vedotin-piiq was granted accelerated approval for use in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified,...

Advertisement

FDA OCE and Syapse Announce Research Collaboration Focused on Regulatory Use of Real-World Evidence

Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signed a multiyear research collaboration agreement focused on the use of real-world evidence to support regulatory decision-making. Syapse and the OCE will work with stakeholders across the FDA to...

Lymphoma
Immunotherapy

Jason Westin, MD, on Diffuse Large B-Cell Lymphoma: Rituximab, Lenalidomide, and Ibrutinib Prior to Chemotherapy

Lung Cancer

Atezolizumab Combined With Chemotherapy in First-Line Extensive-Stage Small Cell Lung Cancer

On March 18, 2019, atezolizumab was approved for use in combination with carboplatin and etoposide in the first-line treatment of adult patients with extensive-stage small cell lung cance (SCLC).1,2 Supporting Efficacy Data Approval was based on findings in the phase III double-blind IMpower133...

Share ASCO Answers Fact Sheets With Your Patients

ASCO Answers are the ideal take-home resource for your patients. Direct, easy to understand, and in a convenient single-page format, ASCO Answers fact sheets introduce patients and their caregivers to types of cancer and cancer-related topics, including treatments and side effects. Each fact sheet...

FDA Approves Fedratinib for Myelofibrosis

Today, the U.S. Food and Drug Administration (FDA) approved fedratinib (Inrebic) for adults with intermediate-2 or high-risk primary or secondary (postpolycythemia vera or postessential thrombocythemia) myelofibrosis. “Prior to today, there was one FDA-approved drug to treat patients with...

Breast Cancer

Adam Brufsky, MD, PhD, on HER2-Positive Metastatic Breast Cancer: NALA Trial on Neratinib vs Lapatinib Plus Capecitabine

ASH Honors Richard Aster, MD, With the Wallace H. Coulter Award for Lifetime Achievement in Hematology

The American Society of Hematology (ASH) will recognize Richard Aster, MD, of the Medical College of Wisconsin and Versiti Blood Center of Wisconsin in Milwaukee with the 2019 Wallace H. Coulter Award for Lifetime Achievement in Hematology. Dr. Aster will be honored for his significant...

Advertisement

FDA Pipeline: Designation in CLL, New Drug Application in GIST, New Prostate Ablation System Receives 510(k) Clearance

Recently, the U.S. Food and Drug Administration granted Breakthrough Therapy designation to acalabrutinib in chronic lymphocytic leukemia (CLL), accepted a new drug application for avapritinib in some types of gastrointestinal stromal tumors (GIST), and granted 501(k) clearance to market the...